Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Does the Inflammatory Bowel Disease Treatment Market Forecast Reveal about the Market’s Historic and Predicted Growth?
The inflammatory bowel disease treatment market size has shown significant growth in recent years. The market size is projected to rise from $25.26 billion in 2024 to $27.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. Factors such as increased prevalence of inflammatory bowel disease, growing demand for biologics and immunomodulators, advancements in treatment options, a growing geriatric population, and increased awareness about the disease have contributed to this historic period of growth.
The market size for inflammatory bowel disease treatment is expected to see accelerated growth in the coming years, reaching $40.27 billion in 2029 at a CAGR of 10.1%. The growth in the forecast period can be attributed to factors such as increased investment in research and development activities, growing demand for biosimilars, increasing incidence of inflammatory bowel disease in emerging markets, growing demand for personalized medicine, and integration of precision medicine in IBD treatment. Emerging trends in the forecast period include increasing numbers of product launches and approvals, personalized dosing and treatment plans in IBD management, use of telemedicine for remote monitoring of IBD patients, exploration of microbiome-based therapies for IBD, and adoption of value-based care models in IBD treatment.
Get Your Free Sample of The Global Inflammatory Bowel Disease Treatment Market Report: https://www.thebusinessresearchcompany.com/sample_request?id=6704&type=smp
What Is Driving the Growth of the Inflammatory Bowel Disease Treatment Market?
The growing prevalence of Crohn’s disease and ulcerative colitis significantly impacts the inflammatory bowel disease treatment market growth. Crohn’s disease and ulcerative colitis are inflammatory bowel diseases (IBD) that result in inflammation and ulcers in the digestive tracts. The increasing number of Crohn’s disease and ulcerative colitis cases are projected to galvanize demand for inflammatory bowel disease treatments utilized to reduce bowel inflammation and prevent medical complications. For instance, recent research published in March 2022 in the United States National Library of Medicine, a US-based medical library, states that approximately 1.6 million Americans currently live with inflammatory bowel disease (Crohn’s disease or ulcerative colitis), and around 70,000 new IBD cases are identified yearly in the USA. Therefore, the increasing prevalence of Crohn’s disease and ulcerative colitis is anticipated to amplify the inflammatory bowel disease treatment market growth.
What Are the Main Segments in the Inflammatory Bowel Disease Treatment Market?
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Order your report now for swift delivery: https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report
Which Major Companies Are Influencing the Inflammatory Bowel Disease Treatment Market?
Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology & Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly & Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic – Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.
What Are the Current Emerging Trends in the Inflammatory Bowel Disease Treatment Market?
Technological advancements represent a key trend gaining traction in the inflammatory bowel disease treatment market. Major market players are focusing on AI-driven registries to gain a competitive edge. For example, in May 2024, Verantos, a California-based real-world evidence (RWE) company, unveiled the Inflammatory Bowel Disease Pragmatic Registry. This registry, leveraging advanced AI, generates high-quality real-world evidence (RWE) for ulcerative colitis and Crohn’s disease. The registry aims to aid in the development of effective therapies by offering a comprehensive dataset comprising over 3 billion data points on patient care, enabling biopharma researchers to gain detailed insights into disease severity, treatment effectiveness, and clinical outcomes using both structured and unstructured data from electronic health records.
What Regions Show The Most Growth In The Inflammatory Bowel Disease Treatment Market?
In 2024, North America emerged as the largest sector in the inflammatory bowel disease treatment market. Asia-Pacific is expected to be the fastest-growing region in the forecast period. This report covers the following regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Inflammatory Bowel Disease Treatment Market Report 2025 Offer?
This report provides an in-depth analysis of the inflammatory bowel disease treatment market. Inflammatory bowel disease treatment refers to anti-inflammatory medications commonly used to treat mild to moderate ulcerative colitis, such as Aminosalicylates (Delzicol, Rowasa, and other brands), balsalazide (Colazal), and olsalazine (Dipentum). The Inflammatory Bowel Disease Treatment Market research report from The Business Research Company delivers a global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Purchase the exclusive report now to unlock valuable market insights: https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6704
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
About The Business Research Company
Learn more about The Business Research Company. With over 15000+ reports from 27 industries across 60+ countries, we’ve built a reputation for comprehensive, data-rich research backed by 1,500,000 datasets. Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive forecasts to support informed decision-making.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
